Imprimis Pharmaceuticals (IMMY) Hits New 1-Year High at $4.66

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)’s share price reached a new 52-week high on Thursday . The stock traded as high as $4.66 and last traded at $4.56, with a volume of 1654 shares trading hands. The stock had previously closed at $4.39.

The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 3.66.

In other news, Director Robert J. Kammer sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $3.00, for a total value of $30,000.00. Following the sale, the director now directly owns 909,827 shares of the company’s stock, valued at approximately $2,729,481. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 30,000 shares of company stock worth $102,100 over the last three months. Insiders own 13.78% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Ardsley Advisory Partners raised its stake in shares of Imprimis Pharmaceuticals by 42.9% in the 2nd quarter. Ardsley Advisory Partners now owns 100,000 shares of the specialty pharmaceutical company’s stock valued at $220,000 after acquiring an additional 30,000 shares during the period. Northern Trust Corp raised its stake in shares of Imprimis Pharmaceuticals by 145.8% in the 1st quarter. Northern Trust Corp now owns 67,013 shares of the specialty pharmaceutical company’s stock valued at $118,000 after acquiring an additional 39,750 shares during the period. Granite Investment Partners LLC raised its stake in shares of Imprimis Pharmaceuticals by 153.8% in the 2nd quarter. Granite Investment Partners LLC now owns 170,962 shares of the specialty pharmaceutical company’s stock valued at $376,000 after acquiring an additional 103,607 shares during the period. Birchview Capital LP purchased a new stake in shares of Imprimis Pharmaceuticals in the 2nd quarter valued at approximately $396,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Imprimis Pharmaceuticals by 104.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 117,990 shares of the specialty pharmaceutical company’s stock valued at $328,000 after acquiring an additional 60,248 shares during the period. 8.55% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/11/10/imprimis-pharmaceuticals-immy-hits-new-1-year-high-at-4-66.html.

About Imprimis Pharmaceuticals (NASDAQ:IMMY)

Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications.

Further Reading: How is a Moving Average Calculated?

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit